Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders

Cellular and Molecular Life Sciences

Volumn 73, Issue 13, 2016, Pages 2511-2530

  Kalkman, Hans O ^a,b   Feuerbach, Dominik ^a  

^a NIBR   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Autism; CREB; Dyskinesia; GSK3; Lithium; Nrf2; Suicide

Indexed keywords

1 (5 CHLORO 2,4 DIMETHOXYPHENYL) 3 (5 METHYL 3 ISOXAZOLYL)UREA; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ABT 107; ACETYLCHOLINE; AQW 051; BRADANICLINE; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR STIMULATING AGENT; CHOLINE; ENCENICLINE; GALANTAMINE; GENISTEIN; GLUCOCORTICOID; JNJ 39393406; LITHIUM SALT; MINOCYCLINE; NICOTINIC AGENT; ONDANSETRON; RG 3487; TROPISETRON; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; AUTISM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINESTERASE INHIBITION; DEPRESSION; DRUG MECHANISM; DRUG SELECTIVITY; DYSKINESIA; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY PAIN; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MELANCHOLIA; MULTIPLE SCLEROSIS; NEGATIVE SYNDROME; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; SMOKING; VAGUS NERVE STIMULATION; AGONISTS; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNE SYSTEM; IMMUNOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; HUMANS; IMMUNE SYSTEM; SIGNAL TRANSDUCTION;

EID: 84961176521     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2175-4     Document Type: Review

References (256)

1. Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22:115–126
2. Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 137:22–54. doi:10.1016/j.pharmthera.2012.08.012
3. Dineley KT, Pandya AA, Yakel JL (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 36:96–108. doi:10.1016/j.tips.2014.12.002
4. John D, Shelukhina I, Yanagawa Y, Deuchars J, Henderson Z (2015) Functional alpha7 nicotinic receptors are expressed on immature granule cells of the postnatal dentate gyrus. Brain Res 1601:15–30. doi:10.1016/j.brainres.2014.12.041
5. Shen JX, Yakel JL (2012) Functional alpha7 nicotinic ACh receptors on astrocytes in rat hippocampal CA1 slices. J Mol Neurosci 48:14–21. doi:10.1007/s12031-012-9719-3
6. Vijayaraghavan S, Karami A, Aeinehband S, Behbahani H, Grandien A, Nilsson B, Ekdahl KN, Lindblom RP, Piehl F, Darreh-Shori T (2013) Regulated extracellular choline acetyltransferase activity—the plausible missing link of the distant action of acetylcholine in the cholinergic anti-inflammatory pathway. PLoS One 8:e65936. doi:10.1371/journal.pone.0065936
7. Sinkus ML, Graw S, Freedman R, Ross RG, Lester HA, Leonard S (2015) The human CHRNA7 and CHRFAM7A genes: a review of the genetics, regulation, and function. Neuropharmacology 96:274–288. doi:10.1016/j.neuropharm.2015.02.006
8. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89:337–343. doi:10.1046/j.1471-4159.2004.02347.x
9. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005) Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflamm 2:4. doi:10.1186/1742-2094-2-4
10. Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, Andra M, Matsubayashi H, Sakai N, Kohsaka S, Inoue K, Nakata Y (2006) Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 83:1461–1470. doi:10.1002/jnr.20850
11. Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, Lee DY, Chung ES, Jin BK (2007) Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 26:79–89. doi:10.1111/j.1460-9568.2007.05636.x
12. Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, Fujikawa Y, Maelicke A, Tomimoto H, Taniguchi T, Shimohama S (2010) Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 285:40180–40191. doi:10.1074/jbc.M110.142356
13. Parada E, Egea J, Buendia I, Negredo P, Cunha AC, Cardoso S, Soares MP, Lopez MG (2013) The microglial alpha7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2. Antioxid Redox Signal 19:1135–1148. doi:10.1089/ars.2012.4671
14. Velez-Fort M, Audinat E, Angulo MC (2009) Functional alpha 7-containing nicotinic receptors of NG2-expressing cells in the hippocampus. Glia 57:1104–1114. doi:10.1002/glia.20834
15. Liu Q, Huang Y, Shen J, Steffensen S, Wu J (2012) Functional alpha7beta2 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid beta peptides. BMC Neurosci 13:155. doi:10.1186/1471-2202-13-155
16. Moretti M, Zoli M, George AA, Lukas RJ, Pistillo F, Maskos U, Whiteaker P, Gotti C (2014) The novel alpha7beta2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Mol Pharmacol 86:306–317. doi:10.1124/mol.114.093377
17. Frazier CJ, Strowbridge BW, Papke RL (2003) Nicotinic receptors on local circuit neurons in dentate gyrus: a potential role in regulation of granule cell excitability. J Neurophysiol 89:3018–3028. doi:10.1152/jn.01036.2002
18. Yakel JL (2012) Nicotinic ACh receptors in the hippocampus: role in excitability and plasticity. Nicotine Tob Res 14:1249–1257. doi:10.1093/ntr/nts091
19. Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N (2006) Stimulation of alpha7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes. Shock. 26:358–364. doi:10.1097/01.shk.0000228168.86845.60
20. Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N (2006) Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol 146:116–123. doi:10.1111/j.1365-2249.2006.03169.x
21. Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, Yang L, Valdes-Ferrer SI, Patel NB, Chavan S, Al-Abed Y, Yang H, Tracey KJ (2009) The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 15:195–202. doi:10.2119/molmed.2009.00039
22. Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA (1999) Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 162:3865–3872
23. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405:458–462. doi:10.1038/35013070
24. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421:384–388. doi:10.1038/nature01339
25. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ, Tracey KJ, Ulloa L (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216–1221. doi:10.1038/nm1124
26. de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, Renart J, Atienza G, Serantes R, Cruces J, Sanchez-Pacheco A, Andres-Mateos E, Montiel C (2011) Function of partially duplicated human alpha7 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response. J Biol Chem 286:594–606. doi:10.1074/jbc.M110.180067
27. 2+ response. J Immunol 179:2889–2898
28. De Rosa MJ, Dionisio L, Agriello E, Bouzat C, Esandi Mdel C (2009) Alpha 7 nicotinic acetylcholine receptor modulates lymphocyte activation. Life Sci. 85:444–449. doi:10.1016/j.lfs.2009.07.010
29. Skok MV, Kalashnik EN, Koval LN, Tsetlin VI, Utkin YN, Changeux JP, Grailhe R (2003) Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines. Mol Pharmacol 64:885–889. doi:10.1124/mol.64.4.885
30. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H (2007) Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci 80:2314–2319. doi:10.1016/j.lfs.2007.02.036
31. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, Tracey KJ, Al-Abed Y, Metz CN (2005) Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 201:1113–1123. doi:10.1084/jem.20040463
32. Zia S, Ndoye A, Lee TX, Webber RJ, Grando SA (2000) Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. J Pharmacol Exp Ther 293:973–981
33. Chimienti F, Hogg RC, Plantard L, Lehmann C, Brakch N, Fischer J, Huber M, Bertrand D, Hohl D (2003) Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet 12:3017–3024. doi:10.1093/hmg/ddg320
34. Dowling O, Rochelson B, Way K, Al-Abed Y, Metz CN (2007) Nicotine inhibits cytokine production by placenta cells via NFkappaB: potential role in pregnancy-induced hypertension. Mol Med 13:576–583. doi:10.2119/2007-00067.Dowling
35. Fu XW, Lindstrom J, Spindel ER (2009) Nicotine activates and up-regulates nicotinic acetylcholine receptors in bronchial epithelial cells. Am J Respir Cell Mol Biol 41:93–99. doi:10.1165/rcmb.2008-0352OC
36. Schedel A, Thornton S, Schloss P, Kluter H, Bugert P (2011) Human platelets express functional alpha7-nicotinic acetylcholine receptors. Arterioscler Thromb Vasc Biol 31:928–934. doi:10.1161/ATVBAHA.110.218297
37. Cancello R, Zulian A, Maestrini S, Mencarelli M, Della Barba A, Invitti C, Liuzzi A, Di Blasio AM (2012) The nicotinic acetylcholine receptor alpha7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by diet-induced weight loss. Int J Obes (Lond) 36:1552–1557. doi:10.1038/ijo.2011.275
38. Waldburger JM, Boyle DL, Pavlov VA, Tracey KJ, Firestein GS (2008) Acetylcholine regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum 58:3439–3449. doi:10.1002/art.23987
39. Fan YY, Yu TS, Wang T, Liu WW, Zhao R, Zhang ST, Ma WX, Zheng JL, Guan DW (2011) Nicotinic acetylcholine receptor alpha7 subunit is time-dependently expressed in distinct cell types during skin wound healing in mice. Histochem Cell Biol 135:375–387. doi:10.1007/s00418-011-0798-y
40. Bray C, Son JH, Meizel S (2005) Acetylcholine causes an increase of intracellular calcium in human sperm. Mol Hum Reprod 11:881–889. doi:10.1093/molehr/gah245
41. Del Signore A, Gotti C, Rizzo A, Moretti M, Paggi P (2004) Nicotinic acetylcholine receptor subtypes in the rat sympathetic ganglion: pharmacological characterization, subcellular distribution and effect of pre- and postganglionic nerve crush. J Neuropathol Exp Neurol 63:138–150
42. Baxter JC, Ramachandra R, Mayne DR, Elmslie KS (2014) Functional expression of alpha7-nicotinic acetylcholine receptors by muscle afferent neurons. J Neurophysiol 112:1549–1558. doi:10.1152/jn.00035.2014
43. Blumenthal EM, Conroy WG, Romano SJ, Kassner PD, Berg DK (1997) Detection of functional nicotinic receptors blocked by alpha-bungarotoxin on PC12 cells and dependence of their expression on post-translational events. J Neurosci 17:6094–6104
44. Peng X, Katz M, Gerzanich V, Anand R, Lindstrom J (1994) Human alpha 7 acetylcholine receptor: cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in Xenopus oocytes. Mol Pharmacol 45:546–554
45. Cooper ST, Millar NS (1997) Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit. J Neurochem 68:2140–2151
46. Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, Ochani M, Ochani K, Yang LH, Hudson L, Lin X, Patel N, Johnson SM, Chavan S, Goldstein RS, Czura CJ, Miller EJ, Al-Abed Y, Tracey KJ, Pavlov VA (2008) Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol Med 14:567–574. doi:10.2119/2008-00079.Parrish
47. Cui WY, Zhao S, Polanowska-Grabowska R, Wang J, Wei J, Dash B, Chang SL, Saucerman JJ, Gu J, Li MD (2013) Identification and characterization of poly(I:C)-induced molecular responses attenuated by nicotine in mouse macrophages. Mol Pharmacol 83:61–72. doi:10.1124/mol.112.081497
48. Moriwaki Y, Watanabe Y, Shinagawa T, Kai M, Miyazawa M, Okuda T, Kawashima K, Yabashi A, Waguri S, Misawa H (2009) Primary sensory neuronal expression of SLURP-1, an endogenous nicotinic acetylcholine receptor ligand. Neurosci Res 64:403–412. doi:10.1016/j.neures.2009.04.014
49. Sugano N, Shimada K, Ito K, Murai S (1998) Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation. Biochem Biophys Res Commun 252:25–28
50. Peng JH, Lucero L, Fryer J, Herl J, Leonard SS, Lukas RJ (1999) Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. Brain Res 825:172–179
51. Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G, Raggenbass M, Feuerbach D, Bertrand D, Fuhrer C (2005) Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci 25:9836–9849. doi:10.1523/JNEUROSCI.3497-05.2005
52. Feuerbach D, Lingenhohl K, Dobbins P, Mosbacher J, Corbett N, Nozulak J, Hoyer D (2005) Coupling of human nicotinic acetylcholine receptors alpha 7 to calcium channels in GH3 cells. Neuropharmacology 48:215–227. doi:10.1016/j.neuropharm.2004.10.003
53. Villiger Y, Szanto I, Jaconi S, Blanchet C, Buisson B, Krause KH, Bertrand D, Romand JA (2002) Expression of an alpha7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes. J Neuroimmunol 126:86–98
54. Jones IW, Wonnacott S (2005) Why doesn’t nicotinic ACh receptor immunoreactivity knock out? Trends Neurosci 28:343–345. doi:10.1016/j.tins.2005.04.010
55. Mogg AJ, Whiteaker P, McIntosh JM, Marks M, Collins AC, Wonnacott S (2002) Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther 302:197–204
56. Gergalova G, Lykhmus O, Komisarenko S, Skok M (2014) alpha7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways. Int J Biochem Cell Biol 49:26–31. doi:10.1016/j.biocel.2014.01.001
57. Lykhmus O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M (2014) Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int J Biochem Cell Biol 53:246–252. doi:10.1016/j.biocel.2014.05.030
58. 2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 35:1–8
59. Sharma G, Vijayaraghavan S (2001) Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 98:4148–4153. doi:10.1073/pnas.071540198
60. Stevens TR, Krueger SR, Fitzsimonds RM, Picciotto MR (2003) Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. J Neurosci 23:10093–10099
61. Cheng Q, Yakel JL (2015) Activation of alpha7 nicotinic acetylcholine receptors increases intracellular cAMP levels via activation of AC1 in hippocampal neurons. Neuropharmacology 95:405–414. doi:10.1016/j.neuropharm.2015.04.016
62. Medeiros R, Castello NA, Cheng D, Kitazawa M, Baglietto-Vargas D, Green KN, Esbenshade TA, Bitner RS, Decker MW, LaFerla FM (2014) alpha7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. Am J Pathol 184:520–529. doi:10.1016/j.ajpath.2013.10.010
63. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276:13541–13546. doi:10.1074/jbc.M008035200
64. Egea J, Buendia I, Parada E, Navarro E, Leon R, Lopez MG (2015) Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol. doi:10.1016/j.bcp.2015.07.032
65. Shaw S, Bencherif M, Marrero MB (2002) Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J Biol Chem 277:44920–44924. doi:10.1074/jbc.M204610200
66. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, Boeckxstaens GE (2005) Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 6:844–851. doi:10.1038/ni1229
67. Pena G, Cai B, Liu J, van der Zanden EP, Deitch EA, de Jonge WJ, Ulloa L (2010) Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis. Eur J Immunol 40:2580–2589. doi:10.1002/eji.201040540
68. Maldifassi MC, Atienza G, Arnalich F, Lopez-Collazo E, Cedillo JL, Martin-Sanchez C, Bordas A, Renart J, Montiel C (2014) A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via alpha7 nicotinic receptors in human macrophages. PLoS One 9:e108397. doi:10.1371/journal.pone.0108397
69. Tracey KJ (2009) Reflex control of immunity. Nat Rev Immunol 9:418–428. doi:10.1038/nri2566
70. Tyagi E, Agrawal R, Nath C, Shukla R (2010) Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation. Innate Immun 16:3–13. doi:10.1177/1753425909104680
71. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, Gallowitsch-Puerta M, Ashok M, Czura CJ, Foxwell B, Tracey KJ, Ulloa L (2006) Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 203:1623–1628. doi:10.1084/jem.20052362
72. Kees MG, Pongratz G, Kees F, Scholmerich J, Straub RH (2003) Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen. J Neuroimmunol 145:77–85
73. Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C, Tusche MW, Pavlov VA, Andersson U, Chavan S, Mak TW, Tracey KJ (2011) Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334:98–101. doi:10.1126/science.1209985
74. Vida G, Pena G, Deitch EA, Ulloa L (2011) alpha7-cholinergic receptor mediates vagal induction of splenic norepinephrine. J Immunol 186:4340–4346. doi:10.4049/jimmunol.1003722
75. Martelli D, McKinley MJ, McAllen RM (2014) The cholinergic anti-inflammatory pathway: a critical review. Auton Neurosci 182:65–69. doi:10.1016/j.autneu.2013.12.007
76. Carrasco-Serrano C, Criado M (2004) Glucocorticoid activation of the neuronal nicotinic acetylcholine receptor alpha7 subunit gene: involvement of transcription factor Egr-1. FEBS Lett 566:247–250. doi:10.1016/j.febslet.2004.04.049
77. Pandya AA, Yakel JL (2013) Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies. Biochem Pharmacol 86:1054–1062. doi:10.1016/j.bcp.2013.05.018
78. Bagdas D, Targowska-Duda KM, Lopez JJ, Perez EG, Arias HR, Damaj MI (2015) The antinociceptive and antiinflammatory properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors in mice. Anesth Analg 121:1369–1377. doi:10.1213/ANE.0000000000000902
79. Kalappa BI, Sun F, Johnson SR, Jin K, Uteshev VV (2013) A positive allosteric modulator of alpha7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia. Br J Pharmacol 169:1862–1878. doi:10.1111/bph.12247
80. Sun F, Jin K, Uteshev VV (2013) A type-II positive allosteric modulator of alpha7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats. PLoS One 8:e73581. doi:10.1371/journal.pone.0073581
81. Gatson JW, Simpkins JW, Uteshev VV (2015) High therapeutic potential of positive allosteric modulation of alpha7 nAChRs in a rat model of traumatic brain injury: proof-of-concept. Brain Res Bull 112:35–41. doi:10.1016/j.brainresbull.2015.01.008
82. Carnevale D, De Simone R, Minghetti L (2007) Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord: Drug Targets 6:388–397
83. Gao Z, Nissen JC, Ji K, Tsirka SE (2014) The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One 9:e107979. doi:10.1371/journal.pone.0107979
84. Cho CH, Song W, Leitzell K, Teo E, Meleth AD, Quick MW, Lester RA (2005) Rapid upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J Neurosci 25:3712–3723. doi:10.1523/JNEUROSCI.5389-03.2005
85. Baer K, Burli T, Huh KH, Wiesner A, Erb-Vogtli S, Gockeritz-Dujmovic D, Moransard M, Nishimune A, Rees MI, Henley JM, Fritschy JM, Fuhrer C (2007) PICK1 interacts with alpha7 neuronal nicotinic acetylcholine receptors and controls their clustering. Mol Cell Neurosci 35:339–355. doi:10.1016/j.mcn.2007.03.009
86. Liu Z, Conroy WG, Stawicki TM, Nai Q, Neff RA, Berg DK (2008) EphB receptors co-distribute with a nicotinic receptor subtype and regulate nicotinic downstream signaling in neurons. Mol Cell Neurosci 38:236–244. doi:10.1016/j.mcn.2008.02.013
87. Castelan F, Castillo M, Mulet J, Sala S, Sala F, Dominguez Del Toro E, Criado M (2008) Molecular characterization and localization of the RIC-3 protein, an effector of nicotinic acetylcholine receptor expression. J Neurochem 105:617–627. doi:10.1111/j.1471-4159.2007.05169.x
88. Grando SA (2008) Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors. J Pharmacol Sci 106:174–179
89. Hoppman-Chaney N, Wain K, Seger PR, Superneau DW, Hodge JC (2013) Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype. Clin Genet 83:345–351. doi:10.1111/j.1399-0004.2012.01925.x
90. Finlay-Schultz J, Canastar A, Short M, El Gazzar M, Coughlan C, Leonard S (2011) Transcriptional repression of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2alpha (AP-2alpha). J Biol Chem 286:42123–42132. doi:10.1074/jbc.M111.276014
91. Yasui DH, Scoles HA, Horike S, Meguro-Horike M, Dunaway KW, Schroeder DI, Lasalle JM (2011) 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain. Hum Mol Genet 20:4311–4323. doi:10.1093/hmg/ddr357
92. de Jonge WJ, Ulloa L (2007) The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151:915–929. doi:10.1038/sj.bjp.0707264
93. Komal P, Estakhr J, Kamran M, Renda A, Nashmi R (2015) cAMP-dependent protein kinase inhibits alpha7 nicotinic receptor activity in layer 1 cortical interneurons through activation of D1/D5 dopamine receptors. J Physiol. doi:10.1113/JP270469
94. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473
95. Dobelis P, Staley KJ, Cooper DC (2012) Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons. PLoS One 7:e41108. doi:10.1371/journal.pone.0041108
96. Wang Y, Xiao C, Indersmitten T, Freedman R, Leonard S, Lester HA (2014) The duplicated alpha7 subunits assemble and form functional nicotinic receptors with the full-length alpha7. J Biol Chem 289:26451–26463. doi:10.1074/jbc.M114.582858
97. Costantini TW, Dang X, Coimbra R, Eliceiri BP, Baird A (2015) CHRFAM7A, a human-specific and partially duplicated alpha7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury. J Leukoc Biol 97:247–257. doi:10.1189/jlb.4RU0814-381R
98. Benfante R, Antonini RA, De Pizzol M, Gotti C, Clementi F, Locati M, Fornasari D (2011) Expression of the alpha7 nAChR subunit duplicate form (CHRFAM7A) is down-regulated in the monocytic cell line THP-1 on treatment with LPS. J Neuroimmunol 230:74–84. doi:10.1016/j.jneuroim.2010.09.008
99. Woolf NJ, Butcher LL (2011) Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 221:488–498. doi:10.1016/j.bbr.2009.12.046
100. Rowe AR, Mercer L, Casetti V, Sendt KV, Giaroli G, Shergill SS, Tracy DK (2015) Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol 29:197–211. doi:10.1177/0269881114564096
101. Briggs CA, McKenna DG (1998) Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 37:1095–1102
102. Wessler I, Kirkpatrick CJ (2008) Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 154:1558–1571. doi:10.1038/bjp.2008.185
103. Quick MW, Lester RA (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53:457–478. doi:10.1002/neu.10109
104. Papke RL, Kem WR, Soti F, Lopez-Hernandez GY, Horenstein NA (2009) Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine. J Pharmacol Exp Ther 329:791–807. doi:10.1124/jpet.108.150151
105. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18:1187–1195
106. Wessler I, Reinheimer T, Klapproth H, Schneider FJ, Racke K, Hammer R (1997) Mammalian glial cells in culture synthesize acetylcholine. Naunyn Schmiedebergs Arch Pharmacol 356:694–697
107. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX (1997) Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9:2734–2742
108. Bencherif M, Narla ST, Stachowiak MS (2014) Alpha7 neuronal nicotinic receptor: a pluripotent target for diseases of the central nervous system. CNS Neurol Disord Drug Targets 13:836–845
109. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A (2008) Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65:409–415. doi:10.1001/archpsyc.65.4.409
110. Kendler KS, Hettema JM, Butera F, Gardner CO, Prescott CA (2003) Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. Arch Gen Psychiatry 60:789–796. doi:10.1001/archpsyc.60.8.789
111. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, Turner RB (2012) Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA 109:5995–5999. doi:10.1073/pnas.1118355109
112. Copeland WE, Wolke D, Lereya ST, Shanahan L, Worthman C, Costello EJ (2014) Childhood bullying involvement predicts low-grade systemic inflammation into adulthood. Proc Natl Acad Sci USA 111:7570–7575. doi:10.1073/pnas.1323641111
113. Slavich GM, Cole SW (2013) The emerging field of human social genomics. Clin Psychol Sci 1:331–348
114. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM (2006) Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 163:1630–1633. doi:10.1176/appi.ajp.163.9.1630
115. Miller GE, Chen E, Fok AK, Walker H, Lim A, Nicholls EF, Cole S, Kobor MS (2009) Low early-life social class leaves a biological residue manifested by decreased glucocorticoid and increased proinflammatory signaling. Proc Natl Acad Sci USA 106:14716–14721. doi:10.1073/pnas.0902971106
116. Weinstein AA, Deuster PA, Francis JL, Bonsall RW, Tracy RP, Kop WJ (2010) Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression. Biol Psychol 84:228–234. doi:10.1016/j.biopsycho.2010.01.016
117. Fang FC (2004) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2:820–832. doi:10.1038/nrmicro1004
118. Sorci G, Faivre B (2009) Inflammation and oxidative stress in vertebrate host-parasite systems. Philos Trans R Soc Lond B Biol Sci 364:71–83. doi:10.1098/rstb.2008.0151
119. Neurauter G, Schrocksnadel K, Scholl-Burgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, Fuchs D (2008) Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 9:622–627
120. Quik M, Zhang D, McGregor M, Bordia T (2015) Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s disease. Biochem Pharmacol. doi:10.1016/j.bcp.2015.06.014
121. Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, Gopalakrishnan M (2009) Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res 1265:65–74. doi:10.1016/j.brainres.2009.01.069
122. Garcia-Oscos F, Pena D, Housini M, Cheng D, Lopez D, Cuevas-Olguin R, Saderi N, Salgado Delgado R, Galindo Charles L, Salgado Burgos H, Rose-John S, Flores G, Kilgard MP, Atzori M (2015) Activation of the anti-inflammatory reflex blocks lipopolysaccharide-induced decrease in synaptic inhibition in the temporal cortex of the rat. J Neurosci Res. 93:859–865. doi:10.1002/jnr.23550
123. Howland RH (2014) Vagus nerve stimulation. Curr Behav Neurosci Rep 1:64–73. doi:10.1007/s40473-014-0010-5
124. Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, Husain MM, Nahas Z, Lisanby SH (2002) Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 51:280–287
125. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ (2005) Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58:355–363. doi:10.1016/j.biopsych.2005.05.024
126. Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, O’Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, Hoff HJ, Padberg F, Muller-Siecheneder F, Audenaert K, van den Abbeele D, Matthews K, Christmas D, Eljamel S, Heuser I (2010) Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol 30:273–281. doi:10.1097/JCP.0b013e3181db8831
127. Slattery DA, Neumann ID (2010) Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology 58:56–61. doi:10.1016/j.neuropharm.2009.06.038
128. McCann MJ, Rogers RC (1990) Oxytocin excites gastric-related neurones in rat dorsal vagal complex. J Physiol 428:95–108
129. Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, Luger A (2008) Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab. 295:E686–E691. doi:10.1152/ajpendo.90263.2008
130. Najjar S, Pearlman DM (2015) Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 161:102–112. doi:10.1016/j.schres.2014.04.041
131. Meyer U (2013) Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42:20–34. doi:10.1016/j.pnpbp.2011.11.003
132. Aberg KA, Liu Y, Bukszar J, McClay JL, Khachane AN, Andreassen OA, Blackwood D, Corvin A, Djurovic S, Gurling H, Ophoff R, Pato CN, Pato MT, Riley B, Webb T, Kendler K, O’Donovan M, Craddock N, Kirov G, Owen M, Rujescu D, St Clair D, Werge T, Hultman CM, Delisi LE, Sullivan P, van den Oord EJ (2013) A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry 70:573–581. doi:10.1001/jamapsychiatry.2013.288
133. Marco C, Antonio D, Antonina S, Alessandro S, Concetta C (2015) Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by schizophrenia and bipolar disorder and controls. Psychiatry Res 228:945–949. doi:10.1016/j.psychres.2015.06.013
134. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS (2008) Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64:820–822. doi:10.1016/j.biopsych.2008.04.025
135. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC (2009) Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50:1801–1807. doi:10.2967/jnumed.109.066647
136. Monji A, Kato T, Kanba S (2009) Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265
137. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671. doi:10.1016/j.biopsych.2011.04.013
138. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, Yoshida S, Arima K, Higuchi T, Amano N, Kunugi H (2013) Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47:401–406. doi:10.1016/j.jpsychires.2012.12.001
139. di Penta A, Moreno B, Reix S, Fernandez-Diez B, Villanueva M, Errea O, Escala N, Vandenbroeck K, Comella JX, Villoslada P (2013) Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 8:e54722. doi:10.1371/journal.pone.0054722
140. Mantyla T, Mantere O, Raij TT, Kieseppa T, Laitinen H, Leiviska J, Torniainen M, Tuominen L, Vaarala O, Suvisaari J (2015) Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis. PLoS One 10:e0125112. doi:10.1371/journal.pone.0125112
141. Chapman S, Ragg M, McGeechan K (2009) Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry 43:277–282. doi:10.1080/00048670802653372
142. Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22–33. doi:10.1016/0006-3223(94)00252-X
143. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E (1999) Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73:1590–1597
144. Guan ZZ, Zhang X, Blennow K, Nordberg A (1999) Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. NeuroReport 10:1779–1782
145. Leonard S, Freedman R (2006) Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry 60:115–122. doi:10.1016/j.biopsych.2006.03.054
146. Masurel-Paulet A, Andrieux J, Callier P, Cuisset JM, Le Caignec C, Holder M, Thauvin-Robinet C, Doray B, Flori E, Alex-Cordier MP, Beri M, Boute O, Delobel B, Dieux A, Vallee L, Jaillard S, Odent S, Isidor B, Beneteau C, Vigneron J, Bilan F, Gilbert-Dussardier B, Dubourg C, Labalme A, Bidon C, Gautier A, Pernes P, Pinoit JM, Huet F, Mugneret F, Aral B, Jonveaux P, Sanlaville D, Faivre L (2010) Delineation of 15q13.3 microdeletions. Clin Genet 78:149–161. doi:10.1111/j.1399-0004.2010.01374.x
147. Gillentine MA, Schaaf CP (2015) The human clinical phenotypes of altered CHRNA7 copy number. Biochem Pharmacol. doi:10.1016/j.bcp.2015.06.012
148. Rakhilin S, Drisdel RC, Sagher D, McGehee DS, Vallejo Y, Green WN (1999) alpha-bungarotoxin receptors contain alpha7 subunits in two different disulfide-bonded conformations. J Cell Biol 146:203–218
149. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R (2002) Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59:1085–1096
150. Sinkus ML, Lee MJ, Gault J, Logel J, Short M, Freedman R, Christian SL, Lyon J, Leonard S (2009) A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia. Brain Res 1291:1–11. doi:10.1016/j.brainres.2009.07.041
151. Hashimoto K (2015) Targeting of alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pharm Des 21:3797–3806
152. Beinat C, Banister SD, Herrera M, Law V, Kassiou M (2015) The therapeutic potential of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs 29:529–542. doi:10.1007/s40263-015-0260-0
153. Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC (2015) Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. doi:10.1038/npp.2015.176
154. Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S (2013) A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology 228:595–602. doi:10.1007/s00213-013-3064-2
155. Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L (2014) A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology 39:1568–1577. doi:10.1038/npp.2014.17
156. Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ (2006) Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 88:102–110. doi:10.1016/j.schres.2006.07.010
157. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38:968–975. doi:10.1038/npp.2012.259
158. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040–1047. doi:10.1176/appi.ajp.2008.07071135
159. Michelmore S, Croskery K, Nozulak J, Hoyer D, Longato R, Weber A, Bouhelal R, Feuerbach D (2002) Study of the calcium dynamics of the human alpha4beta2, alpha3beta4 and alpha1beta1gammadelta nicotinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol 366:235–245. doi:10.1007/s00210-002-0589-z
160. Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D’Souza DC (2014) Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Curr Pharm Des 20:5077–5092
161. Ancin I, Barabash A, Vazquez-Alvarez B, Santos JL, Sanchez-Morla E, Martinez JL, Aparicio A, Pelaez JC, Diaz JA (2010) Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with Schizophrenia. Psychiatr Genet 20:289–297. doi:10.1097/YPG.0b013e32833a9b7a
162. Lisi DM (2002) Lotronex withdrawal. Arch Intern Med 162:101
163. Spiller RC (2011) Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol 11:68–74. doi:10.1016/j.coph.2011.02.005
164. Zhang L, Zhao J (2014) Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat 10:1103–1111. doi:10.2147/NDT.S64236
165. Benazzi F (2007) Bipolar disorder–focus on bipolar II disorder and mixed depression. Lancet 369:935–945. doi:10.1016/S0140-6736(07)60453-X
166. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ (2012) Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 141:1–10. doi:10.1016/j.jad.2011.12.049
167. Maletic V, Raison C (2014) Integrated neurobiology of bipolar disorder. Front Psychiatry 5:98. doi:10.3389/fpsyt.2014.00098
168. Kim HK, Chen W, Andreazza AC (2015) The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder. Neural Plast 2015:408136. doi:10.1155/2015/408136
169. Etain B, Henry C, Bellivier F, Mathieu F, Leboyer M (2008) Beyond genetics: childhood affective trauma in bipolar disorder. Bipolar Disord 10:867–876. doi:10.1111/j.1399-5618.2008.00635.x
170. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:952–955. doi:10.1016/j.pnpbp.2007.02.018
171. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS (2009) Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70:1078–1090. doi:10.4088/JCP.08r04505
172. Munkholm K, Brauner JV, Kessing LV, Vinberg M (2013) Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 47:1119–1133. doi:10.1016/j.jpsychires.2013.05.018
173. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013) Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 74:15–25. doi:10.1016/j.biopsych.2013.01.007
174. Smoller JW (2013) Disorders and borders: psychiatric genetics and nosology. Am J Med Genet B Neuropsychiatr Genet 162B:559–578. doi:10.1002/ajmg.b.32174
175. Rao JS, Harry GJ, Rapoport SI, Kim HW (2010) Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 15:384–392. doi:10.1038/mp.2009.47
176. Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, Olsson B, Zetterberg H, Blennow K, Palsson E, Landen M (2015) Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci 40:250–258
177. Haarman BC, Riemersma-van der Lek RF, de Groot JC, Ruhe HG, Klein HC, Zandstra TE, Burger H, Schoevers RA, de Vries EF, Drexhage HA, Nolen WA, Doorduin J (2014) Neuroinflammation in bipolar disorder—a [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun. 40:219–225. doi:10.1016/j.bbi.2014.03.016
178. Hong CJ, Lai IC, Liou LL, Tsai SJ (2004) Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder. Neurosci Lett 355:69–72
179. Besson M, David V, Baudonnat M, Cazala P, Guilloux JP, Reperant C, Cloez-Tayarani I, Changeux JP, Gardier AM, Granon S (2012) Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology 220:1–14. doi:10.1007/s00213-011-2422-1
180. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273. doi:10.1016/j.cell.2005.05.012
181. Li YC, Gao WJ (2011) GSK-3beta activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev 35:645–654. doi:10.1016/j.neubiorev.2010.08.001
182. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, Wang Q, Chen JG, Wang JZ (2007) Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27:12211–12220. doi:10.1523/JNEUROSCI.3321-07.2007
183. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53:703–717. doi:10.1016/j.neuron.2007.01.029
184. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL (2008) The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153(Suppl 1):S428–S437. doi:10.1038/bjp.2008.2
185. Frank MJ, Fossella JA (2011) Neurogenetics and pharmacology of learning, motivation, and cognition. Neuropsychopharmacology 36:133–152. doi:10.1038/npp.2010.96
186. Lin H, Hsu FC, Baumann BH, Coulter DA, Lynch DR (2014) Cortical synaptic NMDA receptor deficits in alpha7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases. Neurobiol Dis 63:129–140. doi:10.1016/j.nbd.2013.11.021
187. Nolt MJ, Lin Y, Hruska M, Murphy J, Sheffler-Colins SI, Kayser MS, Passer J, Bennett MV, Zukin RS, Dalva MB (2011) EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J Neurosci 31:5353–5364. doi:10.1523/JNEUROSCI.0282-11.2011
188. Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, Gudjonsson SA, Sigurdsson A, Jonasdottir A, Jonasdottir A, Wong WS, Sigurdsson G, Walters GB, Steinberg S, Helgason H, Thorleifsson G, Gudbjartsson DF, Helgason A, Magnusson OT, Thorsteinsdottir U, Stefansson K (2012) Rate of de novo mutations and the importance of father’s age to disease risk. Nature 488:471–475. doi:10.1038/nature11396
189. Le Pichon JB, Yu S, Kibiryeva N, Graf WD, Bittel DC (2013) Genome-wide gene expression in a patient with 15q13.3 homozygous microdeletion syndrome. Eur J Hum Genet 21:1093–1099. doi:10.1038/ejhg.2013.1
190. Ghaleiha A, Ghyasvand M, Mohammadi MR, Farokhnia M, Yadegari N, Tabrizi M, Hajiaghaee R, Yekehtaz H, Akhondzadeh S (2013) Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. J Psychopharmacol 28:677–685. doi:10.1177/0269881113508830
191. Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M, Kalogeromitros D, Theoharides TC (2011) Brief report: “allergic symptoms” in children with autism spectrum disorders. More than meets the eye? J Autism Dev Disord 41:1579–1585. doi:10.1007/s10803-010-1171-z
192. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, Toniato E, Kalogeromitros D (2012) Mast cell activation and autism. Biochim Biophys Acta 1822:34–41. doi:10.1016/j.bbadis.2010.12.017
193. Romagnani S (2002) Cytokines and chemoattractants in allergic inflammation. Mol Immunol 38:881–885
194. Georas SN, Guo J, De Fanis U, Casolaro V (2005) T-helper cell type-2 regulation in allergic disease. Eur Respir J 26:1119–1137. doi:10.1183/09031936.05.00006005
195. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795. doi:10.1172/JCI59643
196. Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, Chen J (2015) Microglial and macrophage polarization-new prospects for brain repair. Nat Rev Neurol 11:56–64. doi:10.1038/nrneurol.2014.207
197. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, Arking DE (2014) Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 5:5748. doi:10.1038/ncomms6748
198. Siegert RJ, Abernethy DA (2005) Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 76:469–475. doi:10.1136/jnnp.2004.054635
199. Stys PK, Zamponi GW, van Minnen J, Geurts JJ (2012) Will the real multiple sclerosis please stand up? Nat Rev Neurosci 13:507–514. doi:10.1038/nrn3275
200. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2:201–211. doi:10.1038/ncpneuro0154
201. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T (2009) Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol. 183:6681–6688. doi:10.4049/jimmunol.0902212
202. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65:1716–1722. doi:10.1212/01.wnl.0000191154.78131.f6
203. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, Asahina M, Fukushi K, Kuwabara S, Hattori T, Suhara T, Irie T (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273–278. doi:10.1212/WNL.0b013e3181ab2b58
204. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–1748. doi:10.1001/archneur.60.12.1745
205. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518. doi:10.1056/NEJMoa041470
206. Stuckenholz V, Bacher M, Balzer-Geldsetzer M, Alvarez-Fischer D, Oertel WH, Dodel RC, Noelker C (2013) The alpha7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. J Parkinsons Dis 3:161–172. doi:10.3233/JPD-120157
207. Suzuki S, Kawamata J, Matsushita T, Matsumura A, Hisahara S, Takata K, Kitamura Y, Kem W, Shimohama S (2013) 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats. J Neurosci Res 91:462–471. doi:10.1002/jnr.23160
208. Liu Y, Zeng X, Hui Y, Zhu C, Wu J, Taylor DH, Ji J, Fan W, Huang Z, Hu J (2015) Activation of alpha7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson’s disease. Neuropharmacology 91:87–96. doi:10.1016/j.neuropharm.2014.11.028
209. Bordia T, Grady SR, McIntosh JM, Quik M (2007) Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson’s disease striatum. Mol Pharmacol 72:52–61. doi:10.1124/mol.107.035998
210. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397. doi:10.1016/S1474-4422(09)70062-6
211. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P (2012) Depression in Parkinson disease—epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47. doi:10.1038/nrneurol.2011.189
212. Jacob EL, Gatto NM, Thompson A, Bordelon Y, Ritz B (2010) Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat Disord 16:576–581. doi:10.1016/j.parkreldis.2010.06.014
213. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Non-motor symptoms in patients with Parkinson’s disease—correlations with inflammatory cytokines in serum. PLoS One 7:e47387. doi:10.1371/journal.pone.0047387
214. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA (2012) The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 92:959–975. doi:10.1189/jlb.0212100
215. Kulak JM, Schneider JS (2004) Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. Brain Res 999:193–202. doi:10.1016/j.brainres.2003.10.062
216. Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T, Lopez Lopez C (2015) AQW051, a novel, potent and selective alpha7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol 172:1292–1304. doi:10.1111/bph.13001
217. Perry VH, Teeling J (2013) Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 35:601–612. doi:10.1007/s00281-013-0382-8
218. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H (2008) IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1–42) by rat primary type 2 microglia. J Immunol 181:6503–6513
219. Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139:313–326. doi:10.1016/j.pharmthera.2013.04.013
220. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT (2010) Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer’s disease. J Neurosci 30:2442–2453. doi:10.1523/JNEUROSCI.5038-09.2010
221. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y (2015) Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. PLoS One 10:e0118333. doi:10.1371/journal.pone.0118333
222. Fratiglioni L, Wang HX (2000) Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies. Behav Brain Res 113:117–120
223. Parri HR, Hernandez CM, Dineley KT (2011) Research update: alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease. Biochem Pharmacol 82:931–942. doi:10.1016/j.bcp.2011.06.039
224. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29:918–929. doi:10.1523/JNEUROSCI.3952-08.2009
225. Thomsen MS, Zwart R, Ursu D, Jensen MM, Pinborg LH, Gilmour G, Wu J, Sher E, Mikkelsen JD (2015) alpha7 and beta2 nicotinic acetylcholine receptor subunits form heteromeric receptor complexes that are expressed in the human cortex and display distinct pharmacological properties. PLoS One 10:e0130572. doi:10.1371/journal.pone.0130572
226. Foster DJ, Jones CK, Conn PJ (2012) Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discov Med 14:413–420
227. Geerts H (2012) alpha7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer’s disease. Expert Opin Investig Drugs 21:59–65. doi:10.1517/13543784.2012.633510
228. Valles AS, Borroni MV, Barrantes FJ (2014) Targeting brain alpha7 nicotinic acetylcholine receptors in Alzheimer’s disease: rationale and current status. CNS Drugs 28:975–987. doi:10.1007/s40263-014-0201-3
229. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638. doi:10.1001/archpsyc.63.6.630
230. Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D (2009) The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56:254–263. doi:10.1016/j.neuropharm.2008.08.025
231. Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, Christians U, Kem WR (2010) Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res 1352:140–146. doi:10.1016/j.brainres.2010.06.063
232. Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du YP, Soti F, Kem WR, Freedman R (2010) Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 35:938–942. doi:10.1038/npp.2009.196
233. Papke RL, Meyer E, Nutter T, Uteshev VV (2000) alpha7 receptor-selective agonists and modes of alpha7 receptor activation. Eur J Pharmacol 393:179–195
234. Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, Briggs CA, Browman KE, Bury D, Curzon P, Drescher KU, Frost JM, Fryer RM, Fox GB, Gronlien JH, Hakerud M, Gubbins EJ, Halm S, Harris R, Helfrich RJ, Kohlhaas KL, Law D, Malysz J, Marsh KC, Martin RL, Meyer MD, Molesky AL, Nikkel AL, Otte S, Pan L, Puttfarcken PS, Radek RJ, Robb HM, Spies E, Thorin-Hagene K, Waring JF, Ween H, Xu H, Gopalakrishnan M, Bunnelle WH (2008) Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther 14:65–82. doi:10.1111/j.1527-3458.2008.00037.x
235. Arias HR, Gu RX, Feuerbach D, Wei DQ (2010) Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor. Biochemistry 49:4169–4180. doi:10.1021/bi901999v
236. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, Konig G (2012) EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099–1110. doi:10.1016/j.neuropharm.2011.10.024
237. Cachelin AB, Rust G (1994) Unusual pharmacology of (+)-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing beta 4 subunits. Mol Pharmacol 46:1168–1174
238. Smyth AM, Lawrie SM (2013) The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci 11:107–117. doi:10.9758/cpn.2013.11.3.107
239. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B (2008) Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42:151–157. doi:10.1016/j.jpsychires.2006.10.013
240. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L (2011) Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 25:335–339. doi:10.1016/j.bbi.2010.10.010
241. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, Brundin L (2013) Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38:743–752. doi:10.1038/npp.2012.248
242. Schnieder TP, Trencevska I, Rosoklija G, Stankov A, Mann JJ, Smiley J, Dwork AJ (2014) Microglia of prefrontal white matter in suicide. J Neuropathol Exp Neurol 73:880–890. doi:10.1097/NEN.0000000000000107
243. Brundin L, Erhardt S, Bryleva EY, Achtyes ED, Postolache TT (2015) The role of inflammation in suicidal behaviour. Acta Psychiatr Scand 132:192–203. doi:10.1111/acps.12458
244. Freland L, Beaulieu JM (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5:14. doi:10.3389/fnmol.2012.00014
245. Beurel E, Michalek SM, Jope RS (2010) Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 31:24–31. doi:10.1016/j.it.2009.09.007
246. Baldessarini RJ, Tondo L, Hennen J (2003) Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 64(Suppl 5):44–52
247. Beurel E, Jope RS (2014) Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry 4:e488. doi:10.1038/tp.2014.129
248. De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, Jope RS (2008) Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 181:338–345
249. Engel T, Hernandez F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26:5083–5090. doi:10.1523/JNEUROSCI.0604-06.2006
250. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F (2010) Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One 5:e14382. doi:10.1371/journal.pone.0014382
251. Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, Le W (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer’s disease transgenic mouse model. J Alzheimers Dis 24:739–749. doi:10.3233/JAD-2011-101875
252. Youdim MB, Arraf Z (2004) Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46:1130–1140. doi:10.1016/j.neuropharm.2004.02.005
253. Lieu CA, Dewey CM, Chinta SJ, Rane A, Rajagopalan S, Batir S, Kim YH, Andersen JK (2014) Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res 1591:111–117. doi:10.1016/j.brainres.2014.10.032
254. Lazzara CA, Riley RR, Rane A, Andersen JK, Kim YH (2015) The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinsons disease therapy. Brain Res 1622:127–136. doi:10.1016/j.brainres.2015.06.018
255. Di Paolo T, Gregoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B (2014) AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 20:1119–1123. doi:10.1016/j.parkreldis.2014.05.007
256. Zhang D, McGregor M, Decker MW, Quik M (2014) The alpha7 nicotinic receptor agonist ABT-107 decreases l-Dopa-induced dyskinesias in parkinsonian monkeys. J Pharmacol Exp Ther 351:25–32. doi:10.1124/jpet.114.216283